Skip to content
No picture yet

Lazcluze 240 mg – DIN 02555972

Lazcluze is Lazertinib Mesylate 240 mg (tablet), sold in Canada. It is used for lung neoplasms. It is supplied by Janssen Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Lazertinib Mesylate 240 mg

Brand
Lazcluze
Strength
240 mg
Used for
Lung neoplasms
Form
Tablet
Manufacturer
Janssen Inc
Drug class
Cancer medicine (kinase inhibitor)
Sold in
Canada
DIN
02555972

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Lazertinib pills and guides

What is Lazertinib used for?

Lazertinib is used for lung neoplasms.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

From the FDA-approved label on DailyMed (published May 07, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02555972.
  • It names Lazcluze, Lazertinib Mesylate 240 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Lazcluze by Janssen Inc.

In Canada: prescription only.

Ingredients

Active: Lazertinib (Lazertinib Mesylate)

Other Lazertinib pills